Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Conditions
Interventions
RO7443904
Glofitamab
+2 more
Locations
9
United States
MSKCC
New York, New York, United States
Cleveland Clinic Foundation; Hematology and Oncology
Cleveland, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Peter MacCallum Cancer Centre; Department of Haematology
Melbourne, Victoria, Australia
Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT
København Ø, Denmark
CHRU Lille - Hôpital Claude Huriez; Service des Maladies du Sang
Lille, France
Start Date
February 18, 2022
Primary Completion Date
July 17, 2024
Completion Date
July 17, 2024
Last Updated
August 23, 2024
NCT06510361
NCT05442515
NCT07162181
NCT06528301
NCT05824585
NCT04460235
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions